Abeona Therapeutics Shares Rise on Higher 2Q Net, Drug Launch

Dow Jones

08/15

By Nicholas G. Miller

Shares of Abeona Therapeutics rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage.

The stock is up 10% to $7.23 and is up 44% over the past 12 months.

The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year.

Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers.

Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

August 14, 2025 14:48 ET (18:48 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2559962969"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559962969\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559962969?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 02:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559962969","market":"sh","top_or_hot":-1,"title":"Abeona Therapeutics Shares Rise on Higher 2Q Net, Drug Launch","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Abeona <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage. \n</p>\n<p>\n  The stock is up 10% to $7.23 and is up 44% over the past 12 months. \n</p>\n<p>\n  The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year. \n</p>\n<p>\n  Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers. \n</p>\n<p>\n  Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 14, 2025 14:48 ET (18:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abeona Therapeutics Shares Rise on Higher 2Q Net, Drug Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbeona Therapeutics Shares Rise on Higher 2Q Net, Drug Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-15 02:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Abeona <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage. \n</p>\n<p>\n  The stock is up 10% to $7.23 and is up 44% over the past 12 months. \n</p>\n<p>\n  The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year. \n</p>\n<p>\n  Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers. \n</p>\n<p>\n  Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 14, 2025 14:48 ET (18:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABEO","symbol_name":"Abeona Therapeutics Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2559962969","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559962969","pubTimestamp":1755197280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Abeona Therapeutics rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage.The stock is up 10% to $7.23 and is up 44% over the past 12 months.The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year.Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers.Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABEO":"Abeona Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Abeona Therapeutics股价因第二季度净值上涨和药物上市而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABEO":1},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Shares of Abeona Therapeutics rose after the company posted higher second-quarter net income and said the launch of its Zavaskyn drug was progressing with strong demand and insurance coverage. \n\n\n  The stock is up 10% to $7.23 and is up 44% over the past 12 months. \n\n\n  The company reported net income of $108.8 million, up from $7.41 million in the prior-year quarter. On a per-share basis, earnings were $1.71, compared with a loss of 26 cents a share last year. \n\n\n  Abeona said it received FDA approval in April for its Zavaskyn drug, which will be used to treat wounds for patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder that causes fragile skin. Abeona said the first treatment is expected in the third quarter and that it had established positive insurance coverage with multiple insurance payers. \n\n\n  Abeona said it would produce enough supply to treat up to 10 patients a month by mid-2026. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 14, 2025 14:48 ET (18:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}